Requirements for quality documentation concerning biological investigational medicinal products in clinical trials

Keywords Biological product, investigational medicinal product (IMP), clinical trial, quality

This document addresses the specific documentation requirements on the biological, chemical and pharmaceutical quality of investigational medicinal product (IMP) containing biological/biotechnology derived substances. It applies to cases where no 'simplified IMP Dossier' is submitted.


Please note that requirements related to the Clinical Trial Regulation will apply only on enty into application of the Regulation. Scientific requirements apply from 26 April 2018.

Document history


How useful was this page?

Add your rating
1 rating